Ottimo Pharma is developing first-in-class, one-of-a-kind PD1/VEGFR2 dual pathway antibodies to extend the lives of people living with cancer.

Ottimo Pharma Strengthens Leadership Team with Senior Appointments 25 February 2025 - Ottimo Pharma (“Ottimo”), an innovative biotech company developing one-of-a-kind PD1/VEGFR2 dual pathway antibodies to extend the lives of patients living with cancer, today announces the appointment of Robert Tighe as Senior Vice President of Preclinical and Translational Sciences, who will be leading Ottimo's preclinical programs and translational strategy, and Katherine Bell-McGuinn as Senior Vice President of Clinical Development, leading Ottimo’s clinical development strategy and execution.
Ottimo Pharma Raises over $140 Million in Series A Financing 19 December 2024 - Ottimo Pharma (“Ottimo”), a private biotech company pioneering bifunctional medicines to extend the lives of people living with cancer, today announces the completion of a Series A financing round of over $140 million. The financing will accelerate the lead asset, Jankistomig, a first-in-class PD1/VEGFR2 bifunctional antibody for multiple solid tumor indications, in both IV and SC forms as well as a pipeline of follow-on bifunctional assets.